SCHEMBL19682585

SCHEMBL19682585

C[C@H](c1cccc2c1-c1ccccc1C2)[C@H](N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 2/20 0.43
POLB P06746 1/20 0.40
SLC1A3 P43003 2/20 0.38
SLC1A2 P43004 2/20 0.38
SLC1A1 P43005 2/20 0.38
SRD5A2 P31213 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
RRM1 P23921 1/20 0.36
RRM2B Q7LG56 1/20 0.36
MAOA P21397 2/20 0.35
CYP1A2 P05177 1/20 0.34
ADRA2A P08913 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2C P28335 1/20 0.34
SLC6A4 P31645 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
ALOX5 P09917 1/20 0.34
HTR2A P28223 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20889261 1.00 HTR2B (0.43) HTR2BPOLBSLC1A3SLC1A2SLC1A1
SCHEMBL19682584 0.83 NPC1 (0.46) HTR2BSLC1A3SLC1A2SLC1A1SRD5A2
SCHEMBL20889365 0.83 NPC1 (0.46) HTR2BSLC1A3SLC1A2SLC1A1SRD5A2
SCHEMBL26461857 0.76 HTR2B (0.44) HTR2BPOLBSRD5A2CHRM2CHRM1
SCHEMBL8160473 0.75 MAOA (0.42) HTR2BPOLBCHRM2CHRM1RRM1
Threonine SCHEMBL29172478 0.73 MEN1 (0.50) HTR2BPOLBSLC1A3SLC1A2SLC1A1
SCHEMBL20889301 0.72 CD274 (0.42) SLC1A3SLC1A2SLC1A1CYP1A2HTR2C
SCHEMBL19682592 0.72 CD274 (0.42) SLC1A3SLC1A2SLC1A1CYP1A2HTR2C
SCHEMBL19682354 0.72 CYP1A2 (0.41) HTR2BPOLBCHRM2CHRM1RRM1
SCHEMBL22310126 0.72 HTR2B (0.43) HTR2BPOLBSRD5A2MAOACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 HTR2B 2889/4885POLB 930/4885SLC1A3 3645/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 HTR2B 2889/4885POLB 930/4885SLC1A3 3645/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 HTR2B 2889/4885POLB 930/4885SLC1A3 3645/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B HTR2B 3462/4885POLB 1214/4885SLC1A3 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.